ICIM Leads the Way in Industrial Workforce Transformation with Certified Compliance, Safety, and ESG Training Programs
VMPL
Lucknow (Uttar Pradesh) [India], May 14: The Institute for Compliance & Industrial Management (ICIM), a Government of Uttar Pradesh-certified institution, is rapidly establishing itself as a national cornerstone in the transformation of India's industrial and corporate workforce. With a mission rooted in real-world education, legal alignment, and sustainable practices, ICIM is setting new benchmarks in industrial capacity building.
Functioning at the vital intersection of education, industry compliance, workplace safety, and social development, ICIM offers structured, government-recognized certification programs that are tailored to meet the evolving needs of India's growing industrial sectors. The institution's approach integrates both Indian statutory frameworks and international best practices to produce professionals who are not only technically sound but also ethically grounded and sustainability-conscious.
Empowering India's Workforce Across Multiple Levels
ICIM's diverse training verticals are designed to serve stakeholders across the industrial spectrum. These include:
* Industrial Workers - With a strong emphasis on occupational safety, statutory compliance, and health awareness, these programs ensure safer workplaces and lower risks across factories and industrial units.
* Corporate Professionals - Modules focused on ESG integration, strategic management, HR compliance, and labour law updates empower professionals to make legally and ethically sound decisions in dynamic business environments.
* Students and Graduates - To bridge the industry-academia gap, ICIM provides skill development and certification programs that equip young individuals with practical knowledge and make them industry-ready from day one.
* Factory Management and HR Teams - Focused training on PoSH (Prevention of Sexual Harassment), industrial relations, and recent labour code reforms help in building progressive and compliant workplaces.
* NGOs and CSR Stakeholders - These programs enable social sector participants to align their projects with industrial accountability and measurable impact frameworks.
The goal is clear: to foster a professional environment where industrial growth is underpinned by legal integrity, operational excellence, and inclusive development.
Leadership Committed to Purpose-Driven Growth
To lead this ambitious agenda, Mr. Satendra Singh has been appointed as the Chairman of ICIM. With years of experience across industrial ecosystems and compliance frameworks, Mr. Singh brings a visionary approach to institutional leadership. Sharing his roadmap in his first public address, he said:
"At ICIM, our mission is to drive excellence in industrial management by fostering fully integrated systems and streamlined processes that deliver operational efficiency and uphold top-tier quality standards. Our vision is to build a compliance-oriented, strategically innovative, and ethically grounded industrial culture across sectors."
He further emphasized the institution's broader mission:
"Our core commitment is to empower industries and corporates to consistently meet and exceed the highest benchmarks of industrial and corporate governance. By bridging training, law, and sustainability, we aim to drive India's industrial workforce towards global competitiveness and long-term resilience."
Legacy, Credibility, and Nationwide Expansion
Backed by a robust team of veteran trainers with over 20 years of real-world experience, ICIM enjoys high credibility in both public and private sector circles. From small manufacturing setups to large corporate entities, the institution is trusted for delivering impactful training programs that create real change.
As ICIM scales its presence across India, its vision encompasses:
* The institutionalization of strong legal compliance frameworks
* Mainstreaming of green and sustainable industrial practices
* Fostering ethical leadership and inclusive growth in business environments
* Enabling seamless collaboration between industry, government bodies, and civil society organizations
ICIM's role is becoming increasingly crucial at a time when India is aiming to become a global manufacturing and industrial hub. The institution's commitment to practical, law-integrated training is expected to play a significant part in making Indian industries future-ready and resilient.
Partnering for Progress
ICIM is actively collaborating with regulatory authorities, corporate houses, academic institutions, and development organizations to broaden its reach and maximize impact. From compliance seminars and industrial workshops to virtual certifications and advisory services, the institution offers a comprehensive suite of learning and development solutions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
36 minutes ago
- Mint
Four Indian pharma stocks that may be hit by US pharma tariff threat
Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from
Hans India
an hour ago
- Hans India
Strong demand, stable activity in economy
India's economic indicators are becoming more supportive of growth, according to the report released by Motilal Oswal Private Wealth (MOPW) on Friday. The report highlights that several positive trends are emerging on the domestic front, including higher GDP growth, easing inflation, and strong tax GDP grew by 7.4 per cent in the fourth quarter of FY25, which is the highest reading in the last four has remained below 4 per cent for four consecutive months, and GST collections have been rising steadily. These signs indicate strong demand and stable activity in the formal sector of the report also notes that India's policy environment is now moving in a unified direction. Fiscal, monetary, and regulatory policies are all aimed at maintaining growth increased tax exemption limits that came into effect from April 2025 are expected to improve disposable incomes and boost the same time, the government's capital expenditure continues to rise, supporting the investment the global front, the environment remains mixed. In April and May, markets faced worries over tariffs and geopolitical tensions. However, the situation improved with a delay in global tariff implementation and a ceasefire announcement between India and Pakistan. This improved global sentiment has helped global equity markets, with the MSCI World Index reaching record highs. Meanwhile, rising bond yields in Japan and China's shift towards gold show that global investors are moving away from US could become a concern as the US faces refinancing of $9 trillion in debt this a weaker Dollar Index could help emerging markets like India by attracting more foreign investments. In the Indian stock market, valuations have increased as earnings have not grown at the same Nifty-50's one-year forward valuation has risen above its long-term average, and mid and small-cap stocks continue to trade at a premium. This makes careful stock selection and active management more important for investors looking to generate higher returns, the report stated.
Hindustan Times
2 hours ago
- Hindustan Times
Yeida: Audit report on stuck JAL projects due by July 16
The Yamuna Expressway Industrial Development Authority (Yeida) on Friday said it has directed consultant firm Currie & Brown to begin study and audit work of stalled Jaiprakash Associates Limited's (JAL's) 12 housing projects and submit the report by July 16. Yeida hired the agency in May for a survey to determine the exact status of the stalled housing projects. (Sunil Ghosh/HT photo) Yeida hired the agency in May for a survey to determine the exact status of the stalled housing projects including apartment towers and plotted development, but JAL failed to complete the survey citing fund crunch, said officials. Thousands of homebuyers are stuck in 12 stalled residential projects of Jaypee Associates Limited along the Yamuna Expressway. The case goes back to 2008, when Yeida allotted about 1,000 hectares of land under the Special Development Zone (SDZ) to Jaypee International Sports, a subsidiary of JP Associates, to build a sports city. The process was halted when JAL challenged the Allahabad high court order in the Supreme Court. Now the matter is pending before the Supreme Court. However since there is no 'stay' over the HC order the Yeida is continuing implementation of the order's directives, said officials. 'We have officially signed an agreement with the Currie & Brown that has been given a month's time to survey and submit the audit by July 16 so that we can get the exact status of the site. The agency in its report will provide the details of the total number of units proposed, and plots planned in JAL's project that was part of Formula One's sports city project. The report will contain the latest details including how many apartments are to be finished and delivered, and how many plots are proposed, and how many plots' possession is given etc,' said Arun Vir Singh, chief executive officer of the Yeida. The Yeida wants to know what percentage of work is incomplete and finished on apartment towers, and also of the plotted area, said Singh. 'Once we have these details, we can figure how much time it will take to complete and deliver the projects, and how much funds we require to deliver justice to thousands of homebuyers. We will be having the exact deadline of all the towers and plotted areas to share with the buyers. Once the survey is done we will also finalize the developer to be engaged to finish and deliver the projects,' said Singh. The project included the Buddh International Circuit, which hosted a MotoGP race in 2023, and several residential developments that were never completed. 'Due to non-payment of dues, Yeida cancelled the land allotment in February 2020. Earlier this year, the Allahabad High Court upheld this cancellation and directed the authority to take over and complete the housing projects,' said Singh. 'We booked a flat in this project in 2011 with hope to get the possession in 2014. But we are still waiting for justice. In 2020 the Yeida cancelled the lease of the project land. JAL took the matter to Allahabad High court that has ordered the Yeida to build the project. Now we hope that we get the possession as the Yeida has assured us, and it is ready to infuse the funds. There are around 8,000 homebuyers who are in distress due to the fault of the Jaypee Associates Limited,' said Shamendra Singh, general secretary of Jaypee Sports City welfare society. The high-level oversight committee includes the Principal secretary of industrial development, the Chairman of UP RERA, a nominated representative, Yeida CEO Arun Vir Singh, a representative from the housing department, and the authorised homebuyer representative. The authority also plans to go ahead with developing international-standard sports infrastructure as originally planned, as per the high court order. As per the Allahabad high court order the Jaiprakash associates Limited has lost the project as the order upheld the Yeida's decision to cancel the lease. Now the Yeida has the lease in its name, and a mandate to build the project.
